MX2017011093A - Terapia combinada de roneparstat para mieloma multiple. - Google Patents
Terapia combinada de roneparstat para mieloma multiple.Info
- Publication number
- MX2017011093A MX2017011093A MX2017011093A MX2017011093A MX2017011093A MX 2017011093 A MX2017011093 A MX 2017011093A MX 2017011093 A MX2017011093 A MX 2017011093A MX 2017011093 A MX2017011093 A MX 2017011093A MX 2017011093 A MX2017011093 A MX 2017011093A
- Authority
- MX
- Mexico
- Prior art keywords
- roneparstat
- multiple myeloma
- combined therapy
- combined
- carfilzomib
- Prior art date
Links
- YUQCJZVVMQZBFE-JPUFUMQZSA-N CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@H]2[C@@H]([C@H]([C@@H](OC2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)NC(=O)C)O[C@@H](CO)C(C(=O)O)O[C@@H](CO)O)CO)OS(=O)(=O)O)O)CO)O)O Chemical compound CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@H]2[C@@H]([C@H]([C@@H](OC2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)NC(=O)C)O[C@@H](CO)C(C(=O)O)O[C@@H](CO)O)CO)OS(=O)(=O)O)O)CO)O)O YUQCJZVVMQZBFE-JPUFUMQZSA-N 0.000 title abstract 3
- 229950003179 roneparstat Drugs 0.000 title abstract 3
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960002438 carfilzomib Drugs 0.000 abstract 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 abstract 1
- 108010021331 carfilzomib Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 abstract 1
- 229960001924 melphalan Drugs 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a roneparstat para su uso en una terapia combinada para el tratamiento de mieloma múltiple. En particular, se ha descubierto inesperadamente que el uso combinado de roneparstat con un inhibidor de proteasoma, en particular seleccionado entre bortezomib y carfilzomib o con melfalán, mejora la eficacia en la disminución de la carga tumoral total, mostrando especialmente sinergismo, con respecto a la administración de cada ingrediente activo solo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129221P | 2015-03-06 | 2015-03-06 | |
| US201562153899P | 2015-04-28 | 2015-04-28 | |
| PCT/IB2016/051196 WO2016142814A1 (en) | 2015-03-06 | 2016-03-03 | Roneparstat combined therapy of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011093A true MX2017011093A (es) | 2018-02-19 |
Family
ID=55521766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011093A MX2017011093A (es) | 2015-03-06 | 2016-03-03 | Terapia combinada de roneparstat para mieloma multiple. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10576101B2 (es) |
| EP (2) | EP3265075B1 (es) |
| JP (1) | JP2018512394A (es) |
| KR (1) | KR20170138405A (es) |
| CN (1) | CN107645954A (es) |
| AU (1) | AU2016230859A1 (es) |
| BR (1) | BR112017018869A2 (es) |
| CA (1) | CA2978040A1 (es) |
| DK (1) | DK3265075T3 (es) |
| ES (1) | ES2715556T3 (es) |
| HK (1) | HK1245107A1 (es) |
| HU (1) | HUE042681T2 (es) |
| MX (1) | MX2017011093A (es) |
| PL (1) | PL3265075T3 (es) |
| PT (1) | PT3265075T (es) |
| WO (1) | WO2016142814A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| EP2343077B1 (en) | 2001-09-12 | 2013-07-17 | SIGMA-TAU Research Switzerland S.A. | Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| US20100009934A1 (en) | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
-
2016
- 2016-03-03 US US15/556,183 patent/US10576101B2/en not_active Expired - Fee Related
- 2016-03-03 BR BR112017018869A patent/BR112017018869A2/pt not_active IP Right Cessation
- 2016-03-03 PT PT16709148T patent/PT3265075T/pt unknown
- 2016-03-03 WO PCT/IB2016/051196 patent/WO2016142814A1/en active Application Filing
- 2016-03-03 DK DK16709148.7T patent/DK3265075T3/en active
- 2016-03-03 EP EP16709148.7A patent/EP3265075B1/en active Active
- 2016-03-03 MX MX2017011093A patent/MX2017011093A/es unknown
- 2016-03-03 CN CN201680012508.0A patent/CN107645954A/zh active Pending
- 2016-03-03 HU HUE16709148A patent/HUE042681T2/hu unknown
- 2016-03-03 CA CA2978040A patent/CA2978040A1/en not_active Abandoned
- 2016-03-03 AU AU2016230859A patent/AU2016230859A1/en not_active Abandoned
- 2016-03-03 JP JP2017546847A patent/JP2018512394A/ja active Pending
- 2016-03-03 PL PL16709148T patent/PL3265075T3/pl unknown
- 2016-03-03 EP EP18202120.4A patent/EP3453389A1/en not_active Withdrawn
- 2016-03-03 ES ES16709148T patent/ES2715556T3/es active Active
- 2016-03-03 KR KR1020177026179A patent/KR20170138405A/ko unknown
-
2018
- 2018-04-09 HK HK18104587.1A patent/HK1245107A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3453389A1 (en) | 2019-03-13 |
| CA2978040A1 (en) | 2016-09-15 |
| DK3265075T3 (en) | 2019-04-08 |
| ES2715556T3 (es) | 2019-06-04 |
| JP2018512394A (ja) | 2018-05-17 |
| HK1245107A1 (zh) | 2018-08-24 |
| BR112017018869A2 (pt) | 2018-04-17 |
| HUE042681T2 (hu) | 2019-07-29 |
| US10576101B2 (en) | 2020-03-03 |
| AU2016230859A1 (en) | 2017-08-17 |
| CN107645954A (zh) | 2018-01-30 |
| KR20170138405A (ko) | 2017-12-15 |
| EP3265075A1 (en) | 2018-01-10 |
| US20180050061A1 (en) | 2018-02-22 |
| PT3265075T (pt) | 2019-03-25 |
| EP3265075B1 (en) | 2018-12-12 |
| PL3265075T3 (pl) | 2020-10-05 |
| WO2016142814A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| TN2016000229A1 (en) | Gabapentinoids and sigma receptor ligands combinations. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| IN2014DN10075A (es) | ||
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| MX2018001684A (es) | Metodo de curacion de heridas. | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| MX2017011093A (es) | Terapia combinada de roneparstat para mieloma multiple. | |
| MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
| MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| MX2017014471A (es) | Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. | |
| PH12015000296B1 (en) | Oral sustained release formulation |